Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Autolus Therapeutics plc as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 120
- +21 vs. Q4 2023
- Shares held
- 175.7M
- +59.7M (+51.5%) vs. Q4 2023
- Total value
- $1.12B
- +$374.0M (+50.1%) vs. Q4 2023
- New holders
- 27
- 46 more added
- Sold out
- 6
- 27 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 83 | $212.0M |
| Q1 2026 | 84 | $184.4M |
| Q4 2025 | 89 | $277.1M |
| Q3 2025 | 96 | $235.7M |
| Q2 2025 | 94 | $378.6M |
| Q1 2025 | 95 | $261.0M |
| Q4 2024 | 110 | $395.4M |
| Q3 2024 | 101 | $648.5M |
| Q2 2024 | 111 | $620.0M |
| Q1 2024 | 120 | $1.12B |
| Q4 2023 | 99 | $746.6M |
| Q3 2023 | 71 | $258.1M |
| Q2 2023 | 69 | $260.4M |
| Q1 2023 | 65 | $195.1M |
| Q4 2022 | 71 | $204.2M |
| Q3 2022 | 66 | $105.7M |
| Q2 2022 | 67 | $143.9M |
| Q1 2022 | 66 | $228.6M |
| Q4 2021 | 73 | $272.3M |
| Q3 2021 | 59 | $164.2M |
| Q2 2021 | 69 | $169.6M |
| Q1 2021 | 63 | $129.4M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Autolus Therapeutics plc; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Simplex Trading, LLC | 7,417 | $47.0K | 0.00% | −6,274−45.8% | Reduced |
| Lazard Asset Management LLC | 7,372 | $46.0K | 0.00% | −4,179−36.2% | Reduced |
| National Asset Management, Inc. | 17,000 | $39.6K | 0.00% | +17,000 | New |
| Aquatic Capital Management LLC | 3,100 | $19.8K | 0.00% | +3,100 | New |
| Quadrant Capital Group LLC | 3,024 | $19.3K | 0.00% | 00.0% | Unchanged |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 2,633 | $16.8K | 0.00% | +2,633 | New |
| Rhumbline Advisers | 2,314 | $14.8K | 0.00% | +1,166+101.6% | Added |
| Lindbrook Capital, LLC | 1,935 | $12.3K | 0.00% | 00.0% | Unchanged |
| Byrne Asset Management LLC | 1,800 | $11.5K | 0.01% | −900−33.3% | Reduced |
| Tower Research Capital LLC (TRC) | 1,616 | $10.3K | 0.00% | −8,177−83.5% | Reduced |
| US Bancorp | 1,384 | $8.83K | 0.00% | 00.0% | Unchanged |
| GAMMA Investing LLC | 1,058 | $6.75K | 0.00% | +751+244.6% | Added |
| NBC Securities, Inc. | 800 | $5.00K | 0.00% | 00.0% | Unchanged |
| Daiwa Securities Group Inc. | 575 | $4.00K | 0.00% | 00.0% | Unchanged |
| Close Asset Management Ltd | 500 | $3.00K | 0.00% | 00.0% | Unchanged |
| Carmichael Hill & Associates, Inc. | 254 | $1.62K | 0.00% | −254−50.0% | Reduced |
| Cubist Systematic Strategies, LLC | 160 | $1.02K | 0.00% | −31,809−99.5% | Reduced |
| Cornerstone Planning Group LLC | 100 | $419 | 0.00% | 00.0% | Unchanged |
| Huntington National Bank | 1 | $6 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 17 | $0 | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −262,694−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −251,361−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −44,633−100.0% | Sold out |
| Sierra Summit Advisors LLC | 0 | $0 | 0.00% | −42,744−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −29,822−100.0% | Sold out |
| Parkside Financial Bank & Trust | 0 | $0 | 0.00% | −200−100.0% | Sold out |